Real-world data reveals outcomes of tucatinib combo after T-DXd in advanced breast cancer

This study looked at medical records of 86 people with HER2+ metastatic breast cancer to see how well a combination of tucatinib, trastuzumab, and capecitabine worked after they had already received a treatment called T-DXd. The goal was to measure things like time until the next treatment or death. The study did not give any new treatment but instead analyzed existing data to understand real-world outcomes.